Suppr超能文献

氟[^18^F]氟代脱氧葡萄糖 PET 用于前列腺癌成像的最新进展。

Update on F-Fluciclovine PET for Prostate Cancer Imaging.

机构信息

Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.

出版信息

J Nucl Med. 2018 May;59(5):733-739. doi: 10.2967/jnumed.117.204032. Epub 2018 Mar 9.

Abstract

PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-F-flurocyclobutane-1-carboxylic acid (F-fluciclovine) is a nonnaturally occurring amino acid PET radiotracer that was recently approved by the U.S. Food and Drug Administration for detection of suspected recurrent prostate cancer. The tumor-imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer because of increased amino acid metabolism for energy and protein synthesis. This continuing medical education article provides an overview on F-fluciclovine PET diagnostic capabilities for primary and metastatic disease, including reviews of published comparisons to conventional imaging and other molecular imaging agents. Additionally, the imaging procedure and image interpretation are detailed, including physiologic and pathologic uptake patterns and pitfalls.

摘要

正电子发射断层扫描(PET)是一种功能成像方法,可利用肿瘤生物学的各个方面,比形态成像单独提供更能检测前列腺癌。1-氨基-3-氟环丁烷-1-羧酸(F-氟代赖氨酸)是非天然存在的氨基酸 PET 放射性示踪剂,最近被美国食品和药物管理局批准用于检测可疑的复发性前列腺癌。该放射性示踪剂的肿瘤成像特征反映了前列腺癌中转录上调的跨膜氨基酸转运,因为氨基酸代谢增加以提供能量和蛋白质合成。这篇继续医学教育文章概述了 F-氟代赖氨酸 PET 在原发性和转移性疾病中的诊断能力,包括对已发表的与常规成像和其他分子成像剂的比较的回顾。此外,详细介绍了成像程序和图像解释,包括生理和病理摄取模式和陷阱。

相似文献

1
Update on F-Fluciclovine PET for Prostate Cancer Imaging.
J Nucl Med. 2018 May;59(5):733-739. doi: 10.2967/jnumed.117.204032. Epub 2018 Mar 9.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
J Nucl Med. 2016 Oct;57(Suppl 3):61S-66S. doi: 10.2967/jnumed.115.170209.
4
Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.
8
F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
Eur Radiol. 2018 Aug;28(8):3151-3159. doi: 10.1007/s00330-017-5213-1. Epub 2018 Jan 2.
9
Review of F-Fluciclovine PET for Detection of Recurrent Prostate Cancer.
Radiographics. 2019 May-Jun;39(3):822-841. doi: 10.1148/rg.2019180139.

引用本文的文献

1
Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
Cancer Imaging. 2024 Aug 30;24(1):117. doi: 10.1186/s40644-024-00752-1.
3
Decomposition of medical imaging spending growth between 2010 and 2021 in the US employer-insured population.
Health Aff Sch. 2024 Mar 27;2(3):qxae030. doi: 10.1093/haschl/qxae030. eCollection 2024 Mar.
4
PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.
Cancer J. 2024;30(3):159-169. doi: 10.1097/PPO.0000000000000716.
5
Performance and application of the total-body PET/CT scanner: a literature review.
EJNMMI Res. 2024 Apr 12;14(1):38. doi: 10.1186/s13550-023-01059-1.
6
Clinical practice in prostate PET imaging.
Ther Adv Med Oncol. 2023 Nov 22;15:17588359231213618. doi: 10.1177/17588359231213618. eCollection 2023.
7
Traditional and novel imaging modalities for advanced prostate cancer: A critical review.
Urol Ann. 2023 Jul-Sep;15(3):249-255. doi: 10.4103/UA.UA_170_20. Epub 2023 Jul 17.
9
Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R.
Cancers (Basel). 2023 Apr 18;15(8):2345. doi: 10.3390/cancers15082345.
10
Management of Advanced Prostate Cancer in the Precision Oncology Era.
Cancers (Basel). 2023 Apr 29;15(9):2552. doi: 10.3390/cancers15092552.

本文引用的文献

1
F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
Eur Radiol. 2018 Aug;28(8):3151-3159. doi: 10.1007/s00330-017-5213-1. Epub 2018 Jan 2.
2
Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.
J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.
3
5
Prostate Cancer Local Recurrence Detected With Both F-Fluciclovine and PSMA-targeted F-DCFPyL PET/CT.
Urology. 2017 Sep;107:e9-e10. doi: 10.1016/j.urology.2017.06.015. Epub 2017 Jun 19.
6
PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1751-1776. doi: 10.1007/s00259-017-3700-x. Epub 2017 Apr 14.
7
Imaging of Prostate Cancer Using Fluciclovine.
PET Clin. 2017 Apr;12(2):145-157. doi: 10.1016/j.cpet.2016.11.005. Epub 2017 Jan 23.
8
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
9
Is There Use for FDG-PET in Prostate Cancer?
Semin Nucl Med. 2016 Nov;46(6):502-506. doi: 10.1053/j.semnuclmed.2016.07.004. Epub 2016 Sep 3.
10
A PET/MRI study towards finding the optimal [F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):695-703. doi: 10.1007/s00259-016-3562-7. Epub 2016 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验